Article

New dry eye emulsion introduced

A new therapy (Retaine MGD, OCuSOFT) is available for those who have dry eye syndrome and meibomian gland dysfunction.

Rosenberg, TX-A new therapy (Retaine MGD, OCuSOFT) is available for those who have dry eye syndrome and meibomian gland dysfunction.

The company says it’s the only preservative-free oil-in-water emulsion that moisturizes, lubricates, and protects moderately to severely dry eyes. Using a proprietary cationic process (Novasorb) that binds positively charged ions to the negatively charged ocular surface, the product is designed to prolong corneal contact time to enhance comfort. The hypotonicity of the emulsion adds moisture by lowering the salt concentration of tears, and the lipid component is designed to lubricate and protect the surface of the eye.

“OCuSOFT is extremely excited to offer such a unique solution for dry eye therapy,” said Cynthia L. Barratt, president and chief executive officer of OCuSOFT. “We believe [the emulsion] will become the standard of care for those patients suffering from meibomian gland dysfunction as well as moderate to severe dry eyes.”

The emulsion is packaged in 30 single-dose vials. The company plans to expand the line to include additional artificial tear products.

Special discount pricing is available to physicians dispensing the emulsion from their offices, and patients also may order it directly online at www.retainebrand.com.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.